TY - CHAP M1 - Book, Section TI - Tissue-Agnostic Therapies A1 - Fojo, Tito A1 - Bates, Susan E. A2 - Boyiadzis, Michael M. A2 - Fojo, Tito Y1 - 2022 N1 - T2 - Hematology-Oncology Therapy, 3e AB - Tissue-agnostic cancer therapeutics treat cancers based on the mutations they harbor, and it is this genetic change and not the tissue of origin that has led to their regulatory approvals. To date, tissue-agnostic therapeutics have been developed for tumors harboring NTRK mutations, those with mismatch repair deficiencies, and those with high tumor mutational burden. Tissue-agnostic cancer therapeutics are the ultimate goal of precision oncology, and it is hoped additional targets will be added and the number of such drugs will grow SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1187885528 ER -